Prostatype Genomics

Summary of the second half of the year and the full year 2023

Second half of 2023, 1 July 2023 – 31 December 2023
• Net sales amounted to 908 TSEK (414)
• EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -17,797 TSEK (-14,849)
• Cash flow from current operations amounted to -9,938 TSEK (-16,386)
• Total cash flow for the period amounted to -9,269 TSEK (2,677)
• Earnings per share amounted to -0.17 SEK (-0.71)

Full year 2023, 1 January 2023 – 31 December 2023
• Net sales amounted to 1,356 TSEK (683)
• EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -37,372 TSEK (-26,785)
• Cash flow from current operations amounted to -29,138 TSEK (-27,704)
• Total cash flow for the period amounted to -8,793 TSEK (-8,840)
• Earnings per share amounted to -0.35 SEK (-1.27)

CEO Fredrik Persson comments:
“During the second half of 2023, Prostatype Genomics achieved significant progress in three important areas: continued scientific and clinical validation of the clinical benefit of Prostatype® for optimal treatment, establishment of our testing service in selected markets in Europe and Asia, and establishment of the testing service in the United States. We also note a continued sales increase in Europe and in Taiwan, although we are still at relatively low levels. 2024 is expected to become a transformative and highly value-creating year for the company, and it began with several achieved milestones at a rapid pace towards an expected market launch in the United States later this year.”

For more information, please contact:
Fredrik Persson, CEO
Telephone: +46 (0)73 049 77 01
Email: fredrik.persson@prostatypegenomics.com

This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person above, on 2024-02-15, at 08:00 CET.